Description
Dutasmart (Dutasteride) 0.5 mg
Dutasmart 0.5 mg is a dutasteride medicine. Dutasteride is a prescription 5-alpha-reductase inhibitor used for benign prostatic hyperplasia, a non-cancerous enlargement of the prostate. The verified regulated medicine form for dutasteride 0.5 mg is an oral soft capsule; product descriptions that refer to “tablets” should be checked carefully against the official label.
Active Ingredient and Medicine Class
The active ingredient is dutasteride. It belongs to the class of 5-alpha-reductase inhibitors, sometimes described as steroid synthesis inhibitors. This class reduces the activity of the enzyme that converts testosterone into dihydrotestosterone, a hormone that contributes to prostate growth.
Established Medical Uses
Official prescribing information and product characteristics describe dutasteride 0.5 mg as a treatment for symptomatic benign prostatic hyperplasia in men with an enlarged prostate. It is used to improve urinary symptoms and to reduce the risk of acute urinary retention and the need for BPH-related surgery. Some official labels also describe use in combination with tamsulosin for symptomatic BPH in men with enlarged prostates.
How It Works
Dutasteride inhibits both type 1 and type 2 5-alpha-reductase. By lowering dihydrotestosterone levels, it helps slow or reverse hormone-driven prostate enlargement. Over time, this can reduce prostate volume and may improve lower urinary tract symptoms associated with BPH.
Important Safety Information
Dutasteride is contraindicated in pregnancy and in people with known clinically significant hypersensitivity to dutasteride or other 5-alpha-reductase inhibitors. Official labeling warns that the medicine can be absorbed through the skin and may harm a male fetus if exposed during pregnancy.
Important precautions include the effect on prostate-specific antigen (PSA): dutasteride lowers PSA levels by about 50%, so changes in PSA should be interpreted carefully in clinical practice. The medicine has also been associated with a higher incidence of high-grade prostate cancer in studies designed to assess cancer risk reduction, and it is not approved for prostate cancer prevention.
Clinically significant interactions may occur with potent CYP3A4 inhibitors such as ritonavir, ketoconazole, verapamil, diltiazem, and ciprofloxacin, which can increase dutasteride exposure. Official labeling also advises that men should not donate blood for 6 months after the last dose, to reduce the risk of exposure in pregnant transfusion recipients.
Possible Side Effects
The most commonly reported adverse effects involve sexual function. These include decreased libido, erectile dysfunction, ejaculation disorders, reduced semen volume, and related changes in orgasm or ejaculation. Some labels note that sexual adverse reactions may persist after treatment discontinuation, although the role of dutasteride in persistence is uncertain.
Other reported reactions include breast tenderness or enlargement, rash, pruritus, urticaria, localized edema, angioedema, depressed mood, and testicular pain or swelling. As with any medicine, the pattern and frequency of adverse effects can vary between studies and populations.
Scientific Evidence
Human clinical studies and meta-analyses support dutasteride’s ability to improve urinary symptom scores, increase urinary flow, and reduce prostate volume in men with BPH. Evidence also suggests a reduced risk of acute urinary retention and BPH-related surgery in appropriately selected patients.
Comparative reviews indicate that dutasteride and finasteride have broadly similar effects for many BPH outcomes, while sexual adverse effects remain an important limitation of 5-alpha-reductase inhibitor therapy. These findings support dutasteride as an established option for BPH, but not as a guaranteed or universally appropriate treatment.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official patient leaflet, full prescribing information, or an individual assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration: AVODART (dutasteride) soft gelatin capsules, prescribing information
- National Library of Medicine, DailyMed: Dutasteride capsule label
- electronic Medicines Compendium (emc), UK: Dutasteride 0.5 mg soft capsules SmPC
- Taehwan Park et al. Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis. World Journal of Urology, 2014. View scientific article
- Xiao-Jun Wu et al. Dutasteride on benign prostatic hyperplasia: a meta-analysis on randomized clinical trials in 6460 patients. Urology, 2014. View scientific article